Rx Promotion Citations By US FDA Plummet; UCLA Webpage Elicits Final Letter Of 2017
Executive Summary
Last year's record low five letters came as FDA launched flurry of studies on DTC, professional ads; 'Bad Ad' complaints totaled more than 100.
You may also be interested in...
US FDA Advertising Citations Remain Rare In 2018
With only seven letters last year, Office of Prescription Drug Promotion appears to be continuing its enforcement retrenchment as agency reconsiders its approach to Rx communications.
US FDA Reprimands Arog Pharmaceuticals For Promo Of Investigational AML Drug
Third enforcement letter of the year cites meeting exhibit and webpage that suggest crenolanib is safe and effective for an unapproved use.
FDA Rx Drug Promotion Rules Extend To Online Interviews, Pfizer Learns
Agency objects to video interview in which Pfizer spokespeople fail to mention risks of estradiol vaginal ring, in OPDP's second enforcement letter of the year.